WMJ‐8‐B, a novel hydroxamate derivative, induces MDA‐MB‐231 breast cancer cell death via the SHP‐1‐STAT3‐survivin cascade

• Published in: British journal of pharmacology Vol. 174; no. 17; pp. 2941 - 2961
• Main Authors: Chuang, Yu‐Fan, Huang, Shiu‐Wen, Hsu, Ya‐Fen, Yu, Meng‐Chieh, Ou, George, Huang, Wei‐Jan, Hsu, Ming‐Jen
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.09.2017; John Wiley and Sons Inc
• Subjects: Acetylation; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Apoptosis - drug effects; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Cell cycle; Cell death; Cell Line, Tumor; Chromatin; Cyclin-dependent kinase inhibitor p21; Drug discovery; Female; G2 Phase Cell Cycle Checkpoints - drug effects; GTP-binding protein; Histone deacetylase; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylase Inhibitors - therapeutic use; Humans; Hydroxamic Acids - chemistry; Hydroxamic Acids - pharmacology; Immunoblotting; Immunoprecipitation; Inhibitor of Apoptosis Proteins - genetics; Inhibitor of Apoptosis Proteins - metabolism; Lymphocytes B; Mice, Nude; Phosphorylation; Polycyclic Compounds - chemistry; Polycyclic Compounds - pharmacology; Protein phosphatase; Protein Tyrosine Phosphatase, Non-Receptor Type 6 - metabolism; Research Paper; Research Papers; SHP-1 protein; Signal Transduction - drug effects; siRNA; Sp1 protein; Stat3 protein; STAT3 Transcription Factor - metabolism; Survivin; Tubulin; Tumors; Xenografts

Background and Purpose Histone deacetylase (HDAC) inhibitors have been demonstrate to have broad‐spectrum anti‐tumour properties and have attracted lots of attention in the field of drug discovery. However, the underlying anti‐tumour mechanisms of HDAC inhibitors remain incompletely understood. In t...